Program
pomalidomide
Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.
Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.
Drug pagePomalidomide: every studyMany companies study it; this page follows only the 37 they lead. All 160 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 251 open or running | phase 3since Jul 15, 2010 | Nov 7, 2003 | Jan 10, 2027phase 3 · NCT05519085 |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Feb 20, 2012 | Feb 20, 2012 | none ahead |
| Amgenits history only | 20 open or running | phase 2since Nov 22, 2019 | Oct 18, 2016 | none ahead |
| Simcere Pharmaceutical Group | 20 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| Criteriumits history only | 10 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Knight Therapeutics (USA)its history only | 10 open or running | phase 1since Jul 3, 2026 | Jul 3, 2026 | none ahead |
| Megalabsits history only | 11 open or running | phase 1since Sep 15, 2023 | Sep 15, 2023 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Dec 20, 2021 | Dec 20, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Simcere Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2016First study: phase 3 study in Multiple MyelomaFirst studyNCT02916420 · 73 enrolled · China
- Dec 14, 2017Phase 1 study in Multiple MyelomaNCT03424928 · 12 enrolled · China
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
Studies
All 2 Simcere Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03424928Multiple Myeloma · China | 1 | Completed | Jan 29, 2018 | 12 |
| NCT02916420Multiple Myeloma · China | 3 | UNKNOWN | Jun 2018 | 73 |
How it is read
Names in the registry
- “Pomalidomide”, 41 entries
- “pomalidomide”, 4 entries
- “Pomalidomide 4 MG Oral Capsule”, 2 entries
- “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
- “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
Codes read as this program: CC4047.
Conditions, from the studies’ own filings
- Multiple Myeloma, 35 studies
- Primary Myelofibrosis, 2 studies
- Brain Neoplasms, 1 study
- Scleroderma, Systemic, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.